BTNL8

Across TCGA pan-cancer cohorts, BTNL8 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BTNL8 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher BTNL8 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated BTNL8 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, MESO, and SKCM are the cancer types where BTNL8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	III,IV	1.000	0.521	.007	26	view →
MESO	DFS	Median	III,IV	0.082	0.414	.007	18	view →
SKCM	OS	Median	II,III,IV	0.986	0.813	.003	13	view →
SARC	OS	Median	All	0.250	0.766	.030	6	view →
GBM	OS	Median	All	0.153	0.414	.024	3	view →
LGG	DFS	Median	All	0.201	0.728	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BTNL8–UCEC (DFS)

Open the UCEC breakdown →